1. Home
  2. LPCN

LPCN

Lipocine Inc.

Logo Lipocine Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 3:31pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.

Founded: N/A Country:
United States
United States
Employees: N/A City: SALT LAKE CITY
Market Cap: 30.7M IPO Year: N/A
Target Price: $33.00 AVG Volume (30 days): 32.6K
Analyst Decision: Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.14 EPS Growth: N/A
52 Week Low/High: $2.31 - $7.14 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 702.03%

Share on Social Networks: